Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.

NCT00785577 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00785577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00785577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
June 30, 2010
Enrollment
273 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathy, painful